跳轉至內容
Merck
全部照片(1)

Key Documents

Y0000288

吡拉西坦

European Pharmacopoeia (EP) Reference Standard

同義詞:

2-氧代-1-吡咯烷乙酰胺, 吡拉西坦

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C6H10N2O2
CAS號碼:
分子量::
142.16
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

piracetam

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

NC(=O)CN1CCCC1=O

InChI

1S/C6H10N2O2/c7-5(9)4-8-3-1-2-6(8)10/h1-4H2,(H2,7,9)

InChI 密鑰

GMZVRMREEHBGGF-UHFFFAOYSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Piracetam EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

相關產品

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

A A Al Hajeri et al.
The Cochrane database of systematic reviews, (2)(2), CD006111-CD006111 (2007-04-20)
Sickle cell disease is one of the most common genetic disorders. Sickle cell crises in which irregular and dehydrated cells contribute to blocking of blood vessels are characterised by episodes of pain. Treatment is mainly supportive and symptomatic. In vitro
S Ricci et al.
The Cochrane database of systematic reviews, (2)(2), CD000419-CD000419 (2006-04-21)
Piracetam has neuroprotective and antithrombotic effects which may help to reduce death and disability in people with acute stroke. The objective of this review was to assess the effects of piracetam in acute presumed ischaemic stroke. We searched the Cochrane
G Justus Hofmeyr et al.
The Cochrane database of systematic reviews, 6(6), CD001064-CD001064 (2012-06-15)
Piracetam is thought to promote the metabolism of brain cells when they are hypoxic. It has been used to prevent adverse effects of fetal distress. The objective of this review was to assess the effects of piracetam for suspected fetal
Fulvio Gualtieri et al.
Current pharmaceutical design, 8(2), 125-138 (2002-01-29)
Cognition enhancers are drugs able to facilitate attentional abilities and acquisition, storage and retrieval of information, and to attenuate the impairment of cognitive functions associated with head traumas, stroke, age and age-related pathologies. Development of cognition enhancers is still a
Philippa C R Wheble et al.
Cerebrovascular diseases (Basel, Switzerland), 25(1-2), 5-11 (2007-11-24)
Piracetam was a candidate neuroprotective drug for acute stroke ineffective in clinical trial. Here we use systematic review and meta-analysis to describe the evidence supporting a protective effect of piracetam and its derivatives in animal models of stroke. We present

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務